{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:36Z","timestamp":1787026956208,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and despite advances in therapy, relapse remains a major cause of treatment failure. Liquid biopsy has emerged as a powerful, minimally invasive tool for real-time disease monitoring and prognostication in hematologic malignancies. This review summarizes recent progress in the application of liquid biopsy technologies in pediatric ALL, focusing on circulating tumor DNA (ctDNA), circulating microRNAs (miRNAs), and extracellular vesicles (EVs). We discuss their respective biological origins, detection platforms, and clinical utilities in diagnosis, risk stratification, and measurable residual disease (MRD) assessment. Particular attention is paid to pediatric-specific challenges such as limited blood volume, pre-analytical variability, and the need for sensitive assays adapted to the pediatric context. Furthermore, we highlight cutting-edge innovations in EV isolation, machine learning-based biomarker integration, and prospective clinical applications. Notably, bone marrow evaluation remains the irreplaceable gold standard for pediatric ALL diagnosis and MRD monitoring. Although most liquid biopsy approaches are still in early translational stages for pediatric ALL, accumulating evidence supports their complementary value for optimizing individualized patient management. Continued validation in large, prospective pediatric cohorts is essential to bring these technologies closer to clinical implementation.<\/jats:p>","DOI":"10.3389\/fonc.2026.1853549","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:32:38Z","timestamp":1782102758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid biopsy in pediatric acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingcong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Children\u2019s Hospital","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091438","article-title":"Advancing leukemia management through liquid biopsy: insights into biomarkers and clinical utility","volume":"17","author":"Hollanda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22783","DOI":"10.1038\/s41598-021-02257-4","article-title":"Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia","volume":"11","author":"Shahid","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41598-023-50628-w","article-title":"Plasma-derived exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia","volume":"14","author":"Saffari","year":"2024","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"28556","DOI":"10.1038\/s41598-024-79733-0","article-title":"Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemia","volume":"14","author":"Peterffy","year":"2024","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091681","article-title":"Extracellular vesicles for childhood cancer liquid biopsy","volume":"16","author":"Singhto","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26846","article-title":"Droplet digital PCR of viral DNA\/RNA, current progress, challenges, and future perspectives","volume":"93","author":"Kojabad","year":"2021","journal-title":"J Med Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2025.0486","article-title":"Non-specific clones hamper the reliability of immunoglobulin light chain gene rearrangements in next-generation sequencing-based measurable residual disease monitoring in pediatric B-cell acute lymphoblastic leukemia: a single-center cohort study","volume":"46","author":"Chen","year":"2026","journal-title":"Ann Lab Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ijms24010146","article-title":"Development of a novel NGS methodology for ultrasensitive circulating tumor DNA detection as a tool for early-stage breast cancer diagnosis","volume":"24","author":"Jim\u00e9nez-Rodr\u00edguez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958673","article-title":"Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia","volume":"12","author":"Sampathi","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12920-020-0671-8","article-title":"Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring","volume":"13","author":"Crowgey","year":"2020","journal-title":"BMC Med Genomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899325","article-title":"Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: a proof of concept study","volume":"12","author":"Arthur","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1173701","article-title":"Liquid biopsies and minimal residual disease in lymphoid Malignancies","volume":"13","author":"Bou Zerdan","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/mop.0000000000001088","article-title":"Liquid biopsies in pediatric oncology: opportunities and obstacles","volume":"34","author":"Sundby","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ol.2024.14681","article-title":"Liquid biopsy: comprehensive overview of circulating tumor DNA (review)","volume":"28","author":"Ge","year":"2024","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41698-024-00657-z","article-title":"A comprehensive overview of liquid biopsy applications in pediatric solid tumors","volume":"8","author":"Janssen","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cimb48050512","article-title":"Next-generation sequencing for minimal residual disease detection in pediatric acute lymphoblastic leukemia: technological advances, clinical translations and current challenges","volume":"48","author":"Liu","year":"2026","journal-title":"Curr Issues Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060805","article-title":"Bioinformatics analysis for circulating cell-free DNA in cancer","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.08.008","article-title":"PCR-free shallow whole genome sequencing for chromosomal copy number detection from plasma of cancer patients is an efficient alternative to the conventional PCR-based approach","volume":"23","author":"Beagan","year":"2021","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj1360","article-title":"Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia","volume":"8","author":"Barsan","year":"2022","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1333943","article-title":"Early prognosis prediction in acute myeloid and acute lymphoid leukemia patients using cell-free DNA concentration ratios","volume":"10","author":"George","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233990","article-title":"Patient-specific circulating tumor DNA for monitoring response to menin inhibitor treatment in preclinical models of infant leukemia","volume":"16","author":"Doculara","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23084","article-title":"Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group","volume":"61","author":"Koleilat","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165869","article-title":"The role of miRNAs as predictors of acute lymphoblastic leukemia chemotherapy toxicity in children: a systematic review","volume":"14","author":"Mitura-Lesiuk","year":"2025","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12967-019-2114-x","article-title":"Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia","volume":"17","author":"Rzepiel","year":"2019","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41102","article-title":"Plasma-based transcriptomic non-coding signature for predicting relapse in pediatric acute lymphoblastic leukemia","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2023.101893","article-title":"MiR-128-3p as blood based liquid biopsy biomarker in childhood acute lymphoblastic leukemia","volume":"67","author":"Rzepiel","year":"2023","journal-title":"Mol Cell Probes"},{"key":"B27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12943-022-01698-3","article-title":"Extracellular vesicle microRNAs contribute to Notch signaling pathway in T-cell acute lymphoblastic leukemia","volume":"21","author":"Colangelo","year":"2022","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014007","article-title":"Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell Malignancies","volume":"139","author":"Izquierdo","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-0024","article-title":"Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2\/Akt\/mTOR signaling","volume":"80","author":"Tohumeken","year":"2020","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-688051","article-title":"Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia","volume":"128","author":"Johnson","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17482","article-title":"Paediatric pre-B acute lymphoblastic leukaemia-derived exosomes regulate immune function in human T cells","volume":"26","author":"Gholipour","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1038\/s41598-025-87857-0","article-title":"Circulating lncRNA HOTAIR is a biomarker for pediatric acute lymphoblastic leukemia and mediator of miR-326 exosomal export","volume":"15","author":"Dashti","year":"2025","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr03334d","article-title":"Surface enhanced Raman scattering of extracellular vesicles for cancer diagnostics despite isolation dependent lipoprotein contamination","volume":"13","author":"Koster","year":"2021","journal-title":"Nanoscale"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12032-024-02547-7","article-title":"Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies","volume":"42","author":"Lajevardi","year":"2024","journal-title":"Med Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010119","article-title":"The role of miRNAs in childhood acute lymphoblastic leukemia relapse and the associated molecular mechanisms","volume":"25","author":"Barrios-Palacios","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MA0422-286R","article-title":"Acute lymphoblastic leukemia-secreted miRNAs induce a proinflammatory microenvironment and promote the activation of hematopoietic progenitors","volume":"112","author":"Rios de Los Rios","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430070","article-title":"Minimal residual disease detection in lymphoma: methods, procedures and clinical significance","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70097","article-title":"Cell-free DNA for detection and monitoring of extramedullary AML relapse","volume":"9","author":"Hupe","year":"2025","journal-title":"Hemasphere"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02535-4","article-title":"Overt and covert genetic causes of pediatric acute lymphoblastic leukemia","volume":"39","author":"Stoltze","year":"2025","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02461-x","article-title":"Genomic profiling of circulating tumor DNA for childhood cancers","volume":"39","author":"Lei","year":"2025","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcancer.2017.12.008","article-title":"Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy","volume":"52","author":"Agrawal","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.012","article-title":"Serial assessment of measurable residual disease in medulloblastoma liquid biopsies","volume":"39","author":"Liu","year":"2021","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2017.1299683","article-title":"Using circulating cell-free DNA to monitor personalized cancer therapy","volume":"54","author":"Oellerich","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02319-2","article-title":"Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions","volume":"38","author":"Abou Dalle","year":"2024","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"OF6","DOI":"10.1158\/2159-8290.cd-nb2018-136","article-title":"ClonoSEQ cleared for residual cancer testing","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311362","article-title":"Novel therapeutic approaches in pediatric acute lymphoblastic leukemia","volume":"26","author":"Marrapodi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1159\/000546249","article-title":"Beyond cellular therapies: the expanding role of antibody-driven immunotherapy in pediatric acute lymphoblastic leukemia","volume":"149","author":"McCall","year":"2026","journal-title":"Acta Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285702","article-title":"Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia","volume":"110","author":"Birenboim","year":"2025","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:32:40Z","timestamp":1782102760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1853549"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1853549","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1853549"}}